Compare Adaptive Biotechnologies Corp (ADPT) vs Lamb Weston Holdings Inc (LW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Lamb Weston Holdings Inc — how do they compare? Adaptive Biotechnologies Corp trades at $24.5 (market cap $4.02B), while Lamb Weston Holdings Inc trades at $54.08 (market cap $7.30B). The key difference: Lamb Weston Holdings Inc is the larger of the two by market cap, and Lamb Weston Holdings Inc pays a 2.86% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | LW | |
|---|---|---|
Market Cap | $4.02B | $7.30B |
Sector | Health | Consumer Staples |
52-Week High | $25.45 | $66.57 |
52-Week Low | $12.30 | $38.48 |
Enterprise Value | $4.08B | $11.18B |
Dividend Yield | — | 2.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.46, down 3.66% today but remains near its 52-week high. The stock shows bullish technical signals with improving fundamentals as revenue grew 55% year-over-year to $277M in 2025, while net losses narrowed significantly from -$159M to -$59M. The company's strategic shift to a pure-play MRD diagnostics business following the Immune Medicine separation has generated positive investor sentiment, with 65% of analysts maintaining buy ratings.
Outlook remains cautiously optimistic as ADPT's MRD business demonstrates strong growth potential with 49% YoY revenue expansion. Key risks include persistent negative profitability metrics and execution challenges during the business separation. The consensus price target of $25.50 suggests modest upside potential from current levels, contingent on continued operational improvement.
Lamb Weston (LW) trades at $53.78, up 2.26% with strong technical momentum and bullish moving average signals. The company demonstrates consistent earnings beats with four consecutive quarters exceeding expectations, though net income margin has declined from 18.85% in 2023 to 4.39% currently. Recent Q4 2026 results showed 7% volume growth and earnings beat estimates, while international operations face headwinds. The stock trades near analyst consensus target of $53.86 with institutional accumulation evident.
LW presents a balanced opportunity with volume growth and cost savings supporting earnings, though margin pressure and international weakness pose challenges. The 3.1% dividend yield provides income support, but declining profitability metrics warrant monitoring. Upside appears limited near current levels with most positive catalysts potentially priced in, requiring execution on margin improvement for further re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →
